# US 2024/0002848 A1 · Compositions and methods for suppressing msutz

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002848 A1
- Document ID: US20240002848A1
- Status: Published application
- Kind: A1
- Application number: 18/038,307
- Filed: 2021-11-22
- Published: 2024-01-04
- Earliest claimed: 2020-11-23
- Assignees: THE UNITED STATES GOVERMENT as represented by the DEPARTMENT OF VETERAN'S AFFAIRS
- Applicants: The United States Goverment AS Represented By the Department of Veterans Affairs
- Inventors: Brian Kraemer; Jeanna M. Wheeler; Pamela McMillan; Timothy J. Strovas; Jeremy Baker
- Web page: https://patentgrep.com/patent/US20240002848A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are small interfering RNA (siRNA) molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of mammalian suppressor of tauopathy 2. Also, described herein are the use of said siRNA molecules in the treatment of Alzheimer's disease or dementia, and reducing accumulation of phosphorylated and aggregated human tau.

## Claims

### Claim 1

A composition comprising a nucleic acid sequence or molecule wherein the nucleic acid comprises or consists of a sequence having at least 90% identity to the sequence set forth in:
(SEQ ID NO: 7)
UUUUCUGGUUUCUGUGCCACACUCAGU,
(SEQ ID NO: 9)
UUUUUCUGGUUUCUGUGCCACACUCAG,
(SEQ ID NO: 11)
GUUUUUCUGGUUUCUGUGCCACACUCA,
(SEQ ID NO: 13)
AGUUUUUCUGGUUUCUGUGCCACACUC,
(SEQ ID NO: 15)
AAGUUUUUCUGGUUUCUGUGCCACACU,
(SEQ ID NO: 17)
GCAGGCCAGUACUUGCAGCGCUCCAAA,
(SEQ ID NO: 19)
AAGCAGGGAAGUAACGGCAGAGCUGAC.
(SEQ ID NO: 21)
CAAGCAGGGAAGUAACGGCAGAGCUGA,
(SEQ ID NO: 23)
ACAAGCAGGGAAGUAACGGCAGAGCUG,
(SEQ ID NO: 25)
UACAAGCAGGGAAGUAACGGCAGAGCU
(SEQ ID NO: 27)
UUACAAGCAGGGAAGUAACGGCAGAGC,
(SEQ ID NO: 29)
CUUACAAGCAGGGAAGUAACGGCAGAG,
(SEQ ID NO: 31)
UCUUACAAGCAGGGAAGUAACGGCAGA,
(SEQ ID NO: 33)
UUCUUACAAGCAGGGAAGUAACGGCAG,
(SEQ ID NO: 35)
CACUCAUCUCAGCGUUAGAAAAGCUACC,
(SEQ ID NO: 37)
UCUGGUUUCUGUGCCACACUCAGUUCAC,
(SEQ ID NO: 39)
UACUUGCAGCGCUCCAAAAGUUUUUCUG,
(SEQ ID NO: 41)
UCCCCAUUUUUACAAGCAGGCCAGUACU,
(SEQ ID NO: 43)
GAUGGGGUGAUGGUAGGCACACUCAUCC,
(SEQ ID NO: 45)
UUGGGGAAGGCUUUGCAGGGUGAGAUGG,
(SEQ ID NO: 47)
AAACAUUUUUCAGCAAAUUUACAAUUGG,
(SEQ ID NO: 49)
UAUUUACAAUUUGGGUGAACAAACAAAC,
(SEQ ID NO: 51)
UCUGGUUUAGUACACUUUGCAUCAUAUU,
(SEQ ID NO: 53)
UACUCACAUGAGUGAAGGGACAAUCUGG,
(SEQ ID NO: 55)
UUGGAGACAGUACUGGAAUUCUUCUACU,
(SEQ ID NO: 57)
GUGGUGCUGGUGGUGCAACUGGUUUUGG,
(SEQ ID NO: 59)
ACGGCAGAGCUGACUACUGGAAGGUGGU,
(SEQ ID NO: 61)
CCAUCUUCUUACAAGCAGGGAAGUAACGG,
(SEQ ID NO: 63)
GUUUUGGAUGAUAGAAGGGACAUUCCAU,
(SEQ ID NO: 65)
UACAUUGAGUGUUAAACCUACAAUGUUU,
(SEQ ID NO: 67)
GUAGAAUGUGCAGUCCGGUCUUGUACAU,
(SEQ ID NO: 69)
UGGUGGGACAUUAAUGGUGGGAUGGUAG,
(SEQ ID NO: 71)
UCGAAUCCAUUUCAAGGCAUGUCGUGGU,
or
(SEQ ID NO: 73)
UUAUUCGCUGGUUUGAGGUCGAAUCCAU.

### Claim 2

A siRNA molecule wherein the siRNA molecule specifically targets at least one sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5, SEQ ID NO: 77 and SEQ ID NO: 78 and reduces expression of mammalian suppressor of tauopathy 2 (MSUT2) gene in a cell, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence having at least 90% sequence identity selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73.

### Claim 3 (depends on 2)

The siRNA molecule of claim 2, wherein at least one nucleotide of the siRNA molecule comprises a chemical modification.

### Claim 4 (depends on 3)

The siRNA molecule of claim 3, wherein the chemical modification is on the sense strand, the antisense strand or on both strands of the siRNA molecule.

### Claim 5 (depends on 2)

The siRNA molecule of claim 2, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6-SEQ ID NO: 73.

### Claim 6 (depends on 2)

The siRNA molecule of claim 2, wherein the siRNA molecule comprises or consists of a sense strand which comprises or consists of at least one sequence selected from the group of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64 SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, and SEQ ID NO: 72; and an antisense strand which is complementary to the sense strand which is selected from the group of SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65 SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, and SEQ ID NO: 73.

### Claim 7

A pharmaceutical composition, wherein the composition comprises at least one siRNA molecule according to any of the preceding claims.

### Claim 8 (depends on 1)

The composition of claim 1, further comprising a pharmaceutically acceptable carrier.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the pharmaceutically acceptable carrier comprises a lipid-based or polymer-based colloid.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the colloid is a liposome, a hydrogel, a microparticle, a nanoparticle, or a block copolymer micelle.

### Claim 11 (depends on 2, 3, 4, 5, 6)

The siRNA molecule of claims 2 to 6, further comprising a pharmaceutically acceptable carrier.

### Claim 12 (depends on 11)

The siRNA molecule of claim 11, wherein the pharmaceutically acceptable carrier comprises a lipid-based or polymer-based colloid.

### Claim 13 (depends on 12)

The siRNA molecule of claim 12, wherein the siRNA molecule is formulated for intravenous, subcutaneous or intrathecal administration.

### Claim 14

A method of treating Alzheimer's disease or dementia, the method comprising:
administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising the siRNA molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5, SEQ ID NO: 77 and SEQ ID NO: 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73, and wherein the therapeutically effective amount reduces accumulation of phosphorylated and aggregated human tau.

### Claim 15

A method of inhibiting expression of a MSUT2 polynucleotide in a subject, the method comprising administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising the siRNA molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5, SEQ ID NO: 77 and SEQ ID NO: 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73.

### Claim 16

A method of reducing phosphorylated and aggregated human tau protein in a subject, the method comprising administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising the siRNA molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5, SEQ ID NO: 77 and SEQ ID NO: 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73.

### Claim 17

A method of suppressing expression of a MSUT2 polynucleotide in a subject, the method comprising administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising the siRNA molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5, SEQ ID NO: 77 and SEQ ID NO: 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73.

### Claim 18

A method of potentiating a neuroinflammatory response to a pathological tau protein in a subject, the method comprising administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising the siRNA molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5, SEQ ID NO: 77 and SEQ ID NO: 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73.

### Claim 19

A method of decreasing astrocytosis or microgliosis in a subject, the method comprising administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising the siRNA molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5, SEQ ID NO: 77 and SEQ ID NO: 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73.

### Claim 20

A method of reducing neuroinflammation in a subject, the method comprising administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising the siRNA molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5, SEQ ID NO: 77 and SEQ ID NO: 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73.

### Claim 21 (depends on 14, 15, 16, 17, 18, 19, 20)

The method of any of claims 14-20, wherein the subject is identified as being in need of treatment before the administration step.

### Claim 22 (depends on 14, 15, 16, 17, 18, 19, 20, 21)

The method of any of claims 14-21, wherein the subject is a human.

### Claim 23 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any of claims 14-22, further comprising administering a cholinesterase inhibitor to the subject.

### Claim 24 (depends on 23)

The method of claim 23, wherein the cholinesterase inhibitor is galantamine, rivastigmine or donepezil.

### Claim 25 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any of claims 14-24, wherein the subject has Alzheimer's disease.

### Claim 26 (depends on 25)

The method of claim 25, wherein the subject has mild-moderate Alzheimer's disease.

### Claim 27 (depends on 25)

The method of claim 25, wherein the subject has moderate-severe Alzheimer's disease.

### Claim 28 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any of claims 14-24, wherein the subject has dementia.

### Claim 29 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any of claims 14-28, wherein the composition further comprises a pharmaceutically acceptable carrier.

### Claim 30 (depends on 29)

The method of claim 29, wherein the pharmaceutically acceptable carrier comprises a lipid-based or polymer-based colloid.

### Claim 31 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any of claims 14-30, wherein the siRNA molecule is formulated for intravenous, subcutaneous or intrathecal administration.

### Claim 32 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any of claims 14-31, wherein the therapeutically effective amount of the siRNA molecule or a composition comprising the siRNA molecule is administered orally, intramuscularly, intraperitoneally, intravenously, subcutaneously or intrathecally.

### Claim 33

A method of inhibiting expression of a MSUT2 polynucleotide, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5, SEQ ID NO: 77 and SEQ ID NO: 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73, wherein the siRNA molecule reduces accumulation of phosphorylated and aggregated tau.

### Claim 34

A method of suppressing expression of a MSUT2 polynucleotide, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5, SEQ ID NO: 77 and SEQ ID NO: 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73, wherein the siRNA molecule reduces accumulation of phosphorylated and aggregated tau.

### Claim 35

A method of potentiating a neuroinflammatory response to a pathological tau protein, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5, SEQ ID NO: 77 and SEQ ID NO: 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73, wherein the siRNA molecule reduces accumulation of phosphorylated and aggregated tau.

### Claim 36

A method of decreasing astrocytosis or microgliosis, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5, SEQ ID NO: 77 and SEQ ID NO: 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73, wherein the siRNA molecule reduces accumulation of phosphorylated and aggregated tau.

### Claim 37

A method of reducing neuroinflammation, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 5, SEQ ID NO: 77 and SEQ ID NO: 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO: 6 to SEQ ID NO: 73, wherein the siRNA molecule reduces accumulation of phosphorylated and aggregated tau.

### Claim 38 (depends on 15, 17, 33)

The method of any of claim 15, 17, 33, or 34, wherein the expression of the MSUT2 polynucleotide is inhibited or suppressed by the siRNA molecule is by inhibiting the binding of poly(A) RNA to the MSUT2 polynucleotide.

### Claim 39 (depends on 33, 34, 35, 36)

The method of any of claim 33, 34, 35, 36, or 37, wherein the cell is a mammalian cell.

### Claim 40 (depends on 39)

The method of claim 39, wherein the mammalian cell is a brain cell.

### Claim 41 (depends on 33, 34, 35)

The method of any claims 33-35, wherein at least one nucleotide of the siRNA molecule comprises a chemical modification.

### Claim 42 (depends on 41)

The method of claim 41, wherein the chemical modification is on the sense strand, the antisense strand or on both.

### Claim 43 (depends on 33, 34, 35, 36, 37, 38)

The method of any claims 33-38, wherein the siRNA molecule comprises at least one sequence is selected from the group consisting of SEQ ID NO: 6-SEQ ID NO: 73.

### Claim 44

The method of any of the preceding claims, wherein the siRNA molecule comprises or consists of a sense strand which comprises or consists of at least one sequence selected from the group of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64 SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, and SEQ ID NO: 72; and an antisense strand which is complementary to the sense strand which is selected from the group of SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65 SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, and SEQ ID NO: 73.
